One of Agios Pharmaceuticals' blood cancer treatments demonstrated promise in a Phase I study against solid tumors, but the results fell short of some investors' expectations, sending the company's share value down about 10%.
Chalk up a win for pharma patent challenger Kyle Bass. The U.S. Patent and Trademark Office has agreed to institute trials for 6 of the drug patents he's challenged--and IP shields for Celgene's Revlimid and Shire's Gattex are among them.
Celgene says that its blockbuster hopeful Ozanimod continued to score well against a placebo arm during the maintenance phase of a trial for ulcerative colitis.
Celgene touted postmarket study results of its oral antipsoriasis drug Otezla, which showed that the med works on those who switch over from Pfizer and Amgen's injectable competitor Enbrel (etanercept). Celgene's med is taking on a top dog in Enbrel, whose 2013 sales ($8.8 billion) made it the world's second best selling drug.
Australia's Mesoblast will make the leap from drug discovery as Japanese partner JCR Pharmaceutical received approval to begin sales of an off-the-shelf allogeneic, or regenerative, medical product, Temcell, based on Mesoblast technology, the Sydney Morning Herald reports.
Celgene's Abraxane can't catch a break in England. Soon after losing coverage for pancreatic cancer on the country's dedicated Cancer Drugs Fund, the treatment got another thumbs-down from its official cost-effectiveness watchdogs.
Third Rock Ventures startup Nurix is lending its drug-development prowess to Celgene in exchange for $150 million up front and much more down the line, collaborating on potential treatments for cancer and immunology.
Celgene is anteing $25 million to take the first seat at the players' table for a new academic research consortium that will put their combined antibody engineering platform to work finding next-gen anticancer therapies with commercial potential.
After suffering back-to-back R&D and franchise setbacks, Biogen is beefing up its pipeline with a late-stage autoimmune drug, handing over $60 million in cash and promising up to $484 million in milestones to complete the pact with Mitsubishi Tanabe.
The U.K.'s special cancer drugs fund gave the heave-ho to a slate of treatments, including Roche's cutting-edge breast cancer treatment Kadcyla and Celgene's Abraxane for pancreatic cancer. Drugmakers are hopping mad, cancer treatment charities are despairing--and the fund and some public officials are on the defensive.